Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $30.1 million.

  • Bioventus' Cash from Operations rose 19176.04% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 8771.4%. This contributed to the annual value of $38.8 million for FY2024, which is 12152.12% up from last year.
  • Latest data reveals that Bioventus reported Cash from Operations of $30.1 million as of Q3 2025, which was up 19176.04% from $25.9 million recorded in Q2 2025.
  • Over the past 5 years, Bioventus' Cash from Operations peaked at $30.1 million during Q3 2025, and registered a low of -$21.0 million during Q2 2022.
  • Its 5-year average for Cash from Operations is $5.4 million, with a median of $10.3 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Bioventus' Cash from Operations was 26730.18% (2023), while the steepest drop was 108616.26% (2023).
  • Quarter analysis of 5 years shows Bioventus' Cash from Operations stood at $13.1 million in 2021, then tumbled by 60.02% to $5.2 million in 2022, then soared by 97.83% to $10.4 million in 2023, then skyrocketed by 86.25% to $19.3 million in 2024, then skyrocketed by 55.77% to $30.1 million in 2025.
  • Its last three reported values are $30.1 million in Q3 2025, $25.9 million for Q2 2025, and -$19.3 million during Q1 2025.